Evaluating the Efficacy of Cytokine‐Directed Therapies in the Management of VEXAS Syndrome
ACR Open Rheumatology · 2026-10 · 8 (10)
DOI: 10.1002/acr2.90153 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACR Open Rheumatology, online erschienen am 24.09.2026. Verfasst von Daniel Montes und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To evaluate the efficacy of cytokine‐directed therapies in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory somatic) syndrome using previously proposed treatment response criteria.
Methods
All patients with genetically confirmed VEXAS syndrome who received targeted therapies with JAK inhibitors (JAKi), tumor necrosis factor α inhibitors (TNFαi), or interleukin‐1 (IL‐1) or IL‐6 inhibitors were identified. Clinical and biochemical data were recorded for patients at time of targeted therapy initiation, and at 3‐, 6‐, and 12‐month follow‐up time points. Treatment response was labeled as complete response (CR; normalization of C‐reactive protein [CRP], prednisone 50% improvement in CRP, >50% prednisone dose reduction, improvement or resolution of disease features), treatment failure (TF; worsening CRP, increasing prednisone, worsening of disease features), or no response (not meeting criteria for CR, PR, or TF).
Results
Overall, 52 patients received an IL‐1i, IL‐6i, or JAKi therapy. At six‐month follow‐up, 3 of 19 IL‐6i patients experienced CR, 4 of 19 experienced PR, and 7 of 19 experienced TF. 2 of 17 patients receiving JAKi experienced CR, 3 of 17 experienced PR, and 6 of 17 experienced TF. No patients receiving IL‐1i or TNFαi experienced CR, and only 1 of 5 IL‐1i patients experienced PR. Among those still receiving biologic therapy at 12 months, only 1 of 11 receiving IL‐6i and 0 of 7 receiving JAKi experienced CR.
Conclusion
IL‐6i and JAKi therapies demonstrated limited, unsustained efficacy for management of VEXAS syndrome. IL‐1i and TNFαi therapies were not efficacious. Useful application of previously reported treatment response criteria was demonstrated, but future incorporation of hematologic parameters may be beneficial.
Autor:innen und Institutionen
- Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
- Department of Internal Medicine, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota.
- Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota.
- Department of Internal Medicine, Division of Nephrology, Rochester, Minnesota.
- Department of Internal Medicine, Division of Hematology, Mayo Clinic, Scottsdale, Arizona.
ORCID-Profile: Cynthia S Crowson, Megan M Sullivan, Matthew J Koster
Zitieren
APA
Montes, D., Langenfeld, H. E., Hanson, A. C., Crowson, C. S., Patnaik, M. M., Go, R. S., Kalantari, K., Kusne, Y., Lasho, T., Mangaonkar, A. A., Olteanu, H., Reichard, K. K., Sullivan, M. M., Viswanatha, D. S., Warrington, K. J., & Koster, M. J. (2026). Evaluating the Efficacy of Cytokine‐Directed Therapies in the Management of VEXAS Syndrome. ACR Open Rheumatology, 8(10). https://doi.org/10.1002/acr2.90153
Vancouver
Montes D, Langenfeld HE, Hanson AC, Crowson CS, Patnaik MM, Go RS, et al. Evaluating the Efficacy of Cytokine‐Directed Therapies in the Management of VEXAS Syndrome. ACR Open Rheumatology. 2026;8(10). doi:10.1002/acr2.90153
BibTeX
@article{Montes2026,
author = {Montes, Daniel and Langenfeld, Hannah E and Hanson, Andrew C and Crowson, Cynthia S and Patnaik, Mrinal M and Go, Ronald S and Kalantari, Kambiz and Kusne, Yael and Lasho, Terra and Mangaonkar, Abhishek A and Olteanu, Horatiu and Reichard, Kaaren K and Sullivan, Megan M and Viswanatha, David S and Warrington, Kenneth J and Koster, Matthew J},
title = {Evaluating the Efficacy of Cytokine‐Directed Therapies in the Management of VEXAS Syndrome},
journal = {ACR Open Rheumatology},
year = {2026},
volume = {8},
number = {10},
doi = {10.1002/acr2.90153}
}
EUVIMED